Hemopexin antibodies are essential tools in studying the glycoprotein hemopexin, a key player in heme metabolism. Hemopexin, primarily synthesized in the liver, binds free heme with high affinity, preventing its oxidative toxicity and facilitating its transport to hepatocytes for iron recycling. This function is critical in conditions involving hemolysis, inflammation, or oxidative stress, such as sickle cell disease, sepsis, or neurodegenerative disorders. Antibodies targeting hemopexin enable researchers to detect, quantify, and localize the protein in biological samples, supporting applications like Western blotting, immunohistochemistry, and ELISA.
Monoclonal and polyclonal hemopexin antibodies vary in specificity, with some recognizing conserved epitopes across species (e.g., human, mouse, rat) or domain-specific regions involved in heme binding. These antibodies are pivotal in exploring hemopexin's role in pathological contexts, including its interaction with cellular receptors (e.g., LRP1/CD91) and its anti-inflammatory or cytoprotective effects. Recent studies also investigate hemopexin as a potential biomarker for diseases like Alzheimer's or hemolytic anemias. Additionally, therapeutic strategies leveraging hemopexin antibodies aim to modulate heme scavenging pathways, offering insights into treating heme overload-related conditions. Quality validation, including cross-reactivity and functional assays, ensures reliability in both research and diagnostic settings.